Xtant Medical Stock Price, News & Analysis

Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in surgical solutions for spinal, orthopedic, and woundcare disorders, has announced its participation in the upcoming CG 45th Annual Growth Conference.

CEO Sean Browne and CFO Scott Neils will represent the company at the event, which is scheduled for August 12, 2025, at 3:30 PM ET in Boston, MA. The format will include both one-on-one meetings and a presentation. Interested parties can access the webcast through the provided link.

Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in surgical solutions for spinal, orthopedic, and woundcare disorders, has scheduled its second quarter 2025 financial results announcement for August 12, 2025, before market open.

The company will host a conference call at 8:30 AM ET on the same day, featuring President and CEO Sean Browne and CFO Scott Neils. Investors can access the call through domestic (877-545-0523) and international (973-528-0016) dial-in numbers using passcode 482755. A webcast will be available, with a replay accessible on the company's website after the live call.

Companion Spine LLC has announced a definitive agreement to acquire Paradigm Spine GmbH and its spine implant portfolio from Xtant Medical Holdings (NYSE:XTNT). The acquisition includes the Coflex® and CoFix® spine implants, which have been used to treat over 390,000 patients globally.

The strategic acquisition positions Companion Spine as the world's largest provider of minimally invasive posterior dynamic spine stabilization solutions. The combined portfolio will offer comprehensive treatment options for lumbar spinal stenosis (LSS) and degenerative disc disease (DDD), with products distributed in more than 60 countries.

The transaction is expected to close in Q3 2025, subject to closing conditions. For Xtant Medical, the sale will allow focus on core business while reducing debt and improving their balance sheet.

Xtant Medical (NYSE American: XTNT) has announced agreements to sell its Coflex® and CoFix® spinal implant assets and all OUS entities of Paradigm Spine GmbH to Companion Spine, LLC for $19.2 million. The transaction includes $11 million in cash at closing and $8.2 million in short-term seller financing.

The deal includes a $2.5 million non-refundable cash deposit, with potential for two additional $2.5 million deposits if Companion Spine needs extra time for financing. The transaction is expected to close in Q3 2025, with the promissory note maturing on December 31, 2025.

This strategic divestment will allow Xtant to focus on its core orthobiologics business while improving its balance sheet. Select Xtant commercial team members will transition to Companion Spine to support the products.

Xtant Medical Holdings (NYSE: XTNT) has launched OsteoFactor Pro™, an innovative allogeneic growth factor solution designed to enhance bone healing in orthopedic and spine procedures. The product features a biphasic release profile that promotes bone regeneration through targeted angiogenesis, chemotaxis, and osteogenesis.

This ready-to-use solution is compatible with synthetic, allograft, or autograft scaffolds, offering surgeons versatility in bone regeneration approaches. With this launch, Xtant becomes the first vertically integrated company to provide solutions across all five major orthobiologic categories, including demineralized bone matrix, cellular allografts, synthetics, structural allografts, and growth factors.

Xtant Medical (NYSE American: XTNT) reported strong Q1 2025 financial results with revenue increasing 18% year-over-year to $32.9 million. The company achieved positive net income of $58,000, compared to a net loss of $4.4 million in Q1 2024. Key highlights include gross margin of 61.5%, Adjusted EBITDA of $3.0 million, and positive operating cash flow of $1.3 million. The growth was primarily driven by increased orthobiologics sales and licensing revenue. Xtant recently launched Trivium™, a next-generation demineralized bone matrix allograft, and completed a secondary private sale of shares by OrbiMed Advisors. Based on strong performance, the company increased its 2025 revenue guidance to $127-131 million, representing 8-12% growth.

Xtant Medical Holdings (NYSE American: XTNT), a global medical technology company specializing in surgical solutions for spinal, orthopedic, and woundcare disorders, has scheduled its first quarter 2025 financial results announcement for May 12, 2025, after market close.

The company will host a conference call at 4:30 PM ET on the same day, featuring President and CEO Sean Browne and CFO Scott Neils. Investors can access the call via domestic (888-506-0062) or international (973-528-0011) dial-in numbers using passcode 828748. A webcast replay will be available on the company's website afterward.

Xtant Medical Holdings (NYSE American: XTNT) has launched Trivium™, a next-generation demineralized bone matrix (DBM) allograft featuring advanced PureLoc™ Fiber Technology. The product combines three synergistic elements for enhanced structure, handling, and biological activity.

Trivium's unique design includes intertwined structures and interconnected porosity to support cell attachment and tissue ingrowth. The product utilizes Xtant's proprietary BacteRinse® processing method, which has been clinically proven to preserve bone morphogenetic proteins (BMPs) over two decades.

The new bone graft offers superior moldability for precise placement across various surgical applications and is now available through the company's nationwide network of independent agents.

Xtant Medical Holdings (NYSE: XTNT) announced a significant ownership transition as OrbiMed Advisors completed a secondary private sale of 73.1 million shares to several investors, led by Nantahala Capital Management. The transaction terminated OrbiMed's investor rights agreement, providing Xtant greater strategic flexibility.

The company revealed preliminary Q1 2025 revenue expectations of $32.8-33.1 million, representing an 18-19% growth compared to Q1 2024, driven by orthobiologics and licensing revenue. Management emphasized their strategy to prioritize profitability through focusing on higher-margin orthobiologics and leveraging their Montana manufacturing facility for operational efficiencies.

While Xtant received no proceeds from the transaction, the company agreed to register the resale of shares on Form S-1 with the SEC. The company plans several new product launches to expand beyond spine applications in 2025.